RemeGen’s $4.2 billion licensing deal falls flat with investors
The biopharma firm had fanned excitement over a rights deal for its autoimmune drug but the eventual terms, with just a small portion of upfront cash, left the market disappointed…
No respite for RemeGen as problems and losses pile up
The developer of innovative drugs has sustained a series of blows to its finances, corporate partnerships, management team and star product, leaving investors jittery Key Takeaways: Despite rising revenue, RemeGen…
FAST NEWS: RemeGen scales back A-share fundraising plan
The Latest: Novel drug maker RemeGen Co. Ltd. (9995.HK; 688331.SH) announced Wednesday that it has reduced its fundraising target through a planned issue of new A-shares from a previous 2.55 billion yuan ($350…
RemeGen hopes for pain relief from expanded drug uses
The innovative drug company has so far brought only two products to market, and its high sales expenses make investors worry about fallout from an anti-corruption drive Key Takeaways: RemeGen’s…
Henlius finds elixir in first profits, scraps A-share IPO
The drug maker said last week it will halt plans for a second listing on China’s STAR Market, the same day it announced its first-ever interim profit since its 2019…
Lepu Biopharma gets taste of spring with first revenues
The ADC-focused drug company logged its first-ever sales late last year, kicking of the next phase of its development Key Takeaways: Lepu Biopharma began to sell its first product last…
Kelun-Biotech hopes for IPO booster from new Merck partnership
The company welcomed Merck as new shareholder not long after the pair signed a lucrative licensing agreement for its cutting-edge ADC cancer treatment Key Takeaways: Despite a lack of products…
Recent Articles
RELATED ARTICLES
-
No respite for RemeGen as problems and losses pile up
- Dispute over Covid vaccines casts doubt on Clover Bio recovery
- 3SBio hits the big time with $6 billion cancer drug deal
- CSPC Pharma teases big bucks deals after earnings miss
- HBM notches up another mega deal but is the model sustainable?
- Alphamab stake sale could signal harder times ahead
- Earnings blow for CSPC Pharma as the state drives a hard bargain
